The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis
Open accessAbstract
BACKGROUND AND AIMS: We examined the hypothesis of an anti-inflammatory effect of phosphatidylcholine in ulcerative colitis. METHODS: A phase IIA, double blind, randomised, placebo controlled study was performed in 60 patients with chronic active, non steroid dependent, ulcerative colitis, with a clinical activity index (CAI) of > or = 4. Retarded release phosphatidylcholine rich phospholipids and placebo were administered at a dose of 6 g daily over three months. The primary end point was a change in CAI towards clinical remission (CAI < or = 3) or CAI improvement by > or = 50%. Secondary end points included > or = 50% changes in endoscopic activity index (EAI), histology, and quality of life scores. RESULTS: Induction of clinical remission (CAI < or = 3) as the primary outcome variable was attained by 16 (53%) patients in the phosphatidylcholine treated group compared with three (10%) in the placebo group (p<0.00001). The rate of clinical remission and CAI improvement was 90% in the phosphatidylcholine group and only 10% in the placebo group. A median drop of seven points in the CAI score (70% improvement) was recorded in the phosphatidylcholine group compared with no change in the placebo group. Secondary end point analysis revealed concomitant drops in EAI and histology scores (p = 0.00016 and p = 0.0067 compared with placebo, respectively). Improvement in quality of life was reported by 16 of 29 evaluated patients in the phosphatidylcholine group compared with two of 30 in the placebo group (p = 0.00005). CONCLUSION: Retarded release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Cited by
van der Veen, J. N., Kennelly, J. P., Wan, S., Vance, J. E., Vance, D. E., & Jacobs, R. L. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.04.006 · Cited by 1,514
Michielan, A., & D’Incà, R. (2015) · Mediators of Inflammation · doi:10.1155/2015/628157 · Cited by 709
Targeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from Grapefruit
Wang, B., Zhuang, X., Deng, Z.-B., Jiang, H., Mu, J., Wang, Q., Xiang, X., Guo, H., Zhang, L., Dryden, G., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.190 · Cited by 634
Health effects of dietary phospholipids
Küllenberg, D., Taylor, L. A., Schneider, M., & Massing, U. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-3 · Cited by 561
Pastorelli, L., De Salvo, C., Mercado, J. R., Vecchi, M., & Pizarro, T. T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00280 · Cited by 440
Metadata
- Authors
- Stremmel, W.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-07-01
- Volume
- 54
- Issue
- 7
- Pages
- 966-971
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2050817202
- Cited by
- 176
- References
- 1
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. https://app.cochat.ai/papers/10.1136/gut.2004.052316
- The paper
- Stremmel, W. (2005). Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. https://doi.org/10.1136/gut.2004.052316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.